These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7789332)

  • 1. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period.
    Kimble RB; Matayoshi AB; Vannice JL; Kung VT; Williams C; Pacifici R
    Endocrinology; 1995 Jul; 136(7):3054-61. PubMed ID: 7789332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice.
    Kitazawa R; Kimble RB; Vannice JL; Kung VT; Pacifici R
    J Clin Invest; 1994 Dec; 94(6):2397-406. PubMed ID: 7989596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.
    Kimble RB; Vannice JL; Bloedow DC; Thompson RC; Hopfer W; Kung VT; Brownfield C; Pacifici R
    J Clin Invest; 1994 May; 93(5):1959-67. PubMed ID: 8182127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice.
    Kimble RB; Bain S; Pacifici R
    J Bone Miner Res; 1997 Jun; 12(6):935-41. PubMed ID: 9169353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles of IL-1, IL-6, and TNFalpha in the feeding responses to endotoxin and influenza virus infection in mice.
    Swiergiel AH; Dunn AJ
    Brain Behav Immun; 1999 Sep; 13(3):252-65. PubMed ID: 10469526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent bone-sparing effect of interleukin-1 receptor antagonist: a hypothesis on the role of IL-1 in ovariectomy-induced bone loss.
    Kimble RB; Kitazawa R; Vannice JL; Pacifici R
    Calcif Tissue Int; 1994 Oct; 55(4):260-5. PubMed ID: 7820776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro.
    Burger RA; Grosen EA; Ioli GR; Van Eden ME; Brightbill HD; Gatanaga M; DiSaia PJ; Granger GA; Gatanaga T
    Gynecol Oncol; 1994 Nov; 55(2):294-303. PubMed ID: 7959299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance.
    Colagiovanni DB; Shopp GM
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):397-419. PubMed ID: 8872492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women.
    Abrahamsen B; Shalhoub V; Larson EK; Eriksen EF; Beck-Nielsen H; Marks SC
    Bone; 2000 Feb; 26(2):137-45. PubMed ID: 10678408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein 60 causes osteoclastic bone resorption via toll-like receptor-2 in estrogen deficiency.
    Koh JM; Lee YS; Kim YS; Park SH; Lee SH; Kim HH; Lee MS; Lee KU; Kim GS
    Bone; 2009 Oct; 45(4):650-60. PubMed ID: 19527807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis.
    Perrien DS; Brown EC; Fletcher TW; Irby DJ; Aronson J; Gao GG; Skinner RA; Hogue WR; Feige U; Suva LJ; Ronis MJ; Badger TM; Lumpkin CK
    J Pharmacol Exp Ther; 2002 Dec; 303(3):904-8. PubMed ID: 12438508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats.
    Feige U; Hu YL; Gasser J; Campagnuolo G; Munyakazi L; Bolon B
    Cell Mol Life Sci; 2000 Sep; 57(10):1457-70. PubMed ID: 11078023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel synthetic triazolotriazepine derivative JTT-606 inhibits bone resorption by down-regulation of action and production of bone resorptive factors.
    Chikazu D; Shindo M; Iwasaka T; Katagiri M; Manabe N; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2000 Apr; 15(4):674-82. PubMed ID: 10780859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.
    Seckinger P; Klein-Nulend J; Alander C; Thompson RC; Dayer JM; Raisz LG
    J Immunol; 1990 Dec; 145(12):4181-4. PubMed ID: 2147937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.
    Coxon A; Bolon B; Estrada J; Kaufman S; Scully S; Rattan A; Duryea D; Hu YL; Rex K; Pacheco E; Van G; Zack D; Feige U
    Arthritis Rheum; 2002 Oct; 46(10):2604-12. PubMed ID: 12384918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of tumor necrosis factor and interleukin-1 in endotoxin-induced middle ear effusions.
    Ball SS; Prazma J; Dais CG; Triana RJ; Pillsbury HC
    Ann Otol Rhinol Laryngol; 1997 Aug; 106(8):633-9. PubMed ID: 9270424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
    Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
    Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss.
    Lee SK; Kalinowski JF; Jacquin C; Adams DJ; Gronowicz G; Lorenzo JA
    J Bone Miner Res; 2006 May; 21(5):695-702. PubMed ID: 16734384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.